These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28763691)

  • 1. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
    Su C; Zhou F; Shen J; Zhao J; O'Brien M
    Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC; Neal JW; Niu XM; Wakelee HA
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
    Meoni G; Cecere FL; Lucherini E; Di Costanzo F
    J Geriatr Oncol; 2013 Jul; 4(3):282-90. PubMed ID: 24070465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
    Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
    Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapies for Lung Cancer.
    Stinchcombe TE
    Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
    Minguet J; Smith KH; Bramlage P
    Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in targeted advanced lung cancer therapy in the elderly.
    Losanno T; Gridelli C
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):787-797. PubMed ID: 28656792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeted therapies in non-small cell lung cancer in 2014].
    Leduc C; Besse B
    Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.
    Lo Russo G; Imbimbo M; Garassino MC
    Tumori; 2016 Jun; 2016(3):223-5. PubMed ID: 26979246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
    Perdrizet K; Leighl NB
    Curr Treat Options Oncol; 2019 Feb; 20(3):21. PubMed ID: 30778772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.
    Gandhi L
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):484-485. PubMed ID: 30067619
    [No Abstract]   [Full Text] [Related]  

  • 19. Anaplastic lymphoma kinase inhibitors in elderly patients with advanced non-small cell lung cancer.
    Zaarour M; Nazha B; Weerasinghe C; Moussaly E; Terjanian T
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):877-83. PubMed ID: 27328177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.
    Ess SM; Herrmann C; Frick H; Krapf M; Cerny T; Jochum W; Früh M
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28557060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.